BioCryst Achieves First Full-Year Profitability, Expands HAE Portfolio
Event summary
- BioCryst reported $601.8 million in ORLADEYO® net revenue for 2025, up 38% year-over-year.
- The company achieved full-year profitability for the first time, with $341.0 million in operating profit.
- BioCryst completed the acquisition of Astria Therapeutics, adding navenibart to its HAE portfolio.
- FDA approved ORLADEYO oral pellets for patients aged 2 to <12 years with HAE.
- BioCryst sold its European ORLADEYO business to Neopharmed Gentili S.p.A. for $243.3 million.
The big picture
BioCryst's strategic shift towards focusing on its core U.S. business and expanding its HAE portfolio aligns with broader industry trends of consolidation and specialization in rare disease treatments. The company's first full-year profitability marks a significant milestone, but its ability to maintain this momentum will depend on the success of its pipeline and operational efficiency. The acquisition of Astria Therapeutics and the divestiture of its European business reflect a calculated move to streamline operations and enhance long-term growth prospects.
What we're watching
- Pipeline Progress
- The pace at which BioCryst advances its Phase 1 trial for BCX17725 and the Phase 3 program for navenibart will determine its long-term growth trajectory.
- Market Penetration
- Whether BioCryst can sustain its strong ORLADEYO sales performance in the U.S. amid evolving treatment landscapes.
- Financial Discipline
- How BioCryst manages its operating expenses and cash flow in light of its strategic acquisitions and divestitures.
Related topics